Figure 4.

Staining for caspase-3 protein in a cardiac tissue section of (a) control mice showing no caspase-3 immune-reactive cells; (b) tulathromycin-treated mice showing multiple caspase-3 immune-reactive cells; (c) DFS-treated mice showing abundant caspase-3 immune-reactive cells; (d) tulathromycin–DFS-treated mice showing diffuse, intensely stained caspase-3 immune-reactive cells; (e) tulathromycin–lycopene-treated mice showing fewer caspase-3 immune-reactive cells; (f) DFD–lycopene-treated mice showing sparse caspase-3 immune-reactive cells; (g) tulathromycin–DFS–lycopene-treated mice showing sporadic caspase-3 immune-reactive cells (caspase-3 immunohistochemical staining, ×400); and (h) immunohistochemical scoring of caspase-3 in the heart tissue of control and treated mice. Means carrying different superscripts (a,b,c,d) are significantly different at (p < 0.05).